AstraZeneca remains among the leaders of oncology

AstraZeneca informed investors and analysts about the positive development of its cancer drug Lynparza, which has demonstrated under clinical assessment (Olympiad Phase III) higher efficacy than chemotherapy for the treatment of metastatic breast cancer. Lynparza, a Parp inhibitor, is among the three cancer drugs launched by the UK-based group in the last three years, however it has never received the same attention as durvalumab, currently in advanced-phase clinical trial. Lynparza, launched on the market in 2014, is currently used in 31 countries all over the world for the treatment of ovarian cancer and generates $218m pa in sales. AstraZeneca’s shares rose over 2% (London) after the announcement.
(Source AstraZeneca)